Hyperventilation syndrome Signs and Symptoms Abnormalities of breathing
Conditions
Interventions
Current interventions as of 14/10/2008:
Physiotherapy in the form of breathing retraining:
Participants will be taught relaxed diaphragmatic breathing and encouraged to reduce their breath rate to 6
Sponsors
Physiotherapy Research Foundation (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Any patient newly diagnosed with hyperventilation syndrome by the respiratory physicians at Southampton General Hospital. Added as of 14/10/2008: Both males and females, over 18 years old
Exclusion criteria
Exclusion criteria: 1. Any person for whom acupuncture would be contraindicated e.g. in pregnancy, pacemaker wearers 2. Any person who is receiving conventional or alternative treatment for the condition 3. People who are allergic to sticking plaster 4. People who are unable to attend for the required treatment sessions
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Hospital Anxiety and Depression scale. This is a validated questionnaire which is used to identify anxiety and depression in non-psychiatric hospital clinics. Added as of 14/10/2008: All primary and secondary outcomes are measured at 1) baseline 2) pre-treatment (after a 4-week wait period to ensure participant's condition is stable) and 3) post-treatment on the 9th session. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Nijmegen Questionnaire - this is a validated screening tool which has been shown to have 95% effectiveness in discriminating hyperventilators from normals 2. Measure Yourself Medical Outcome Profile (MYMOP2) - this is a validated quality of life measure, which is individualised and problem specific and also includes general wellbeing 3. Objective measures of cardiorespiratory performance will also be taken e.g. respiratory rate and pattern, resting end tidal carbon dioxide, pulse oximetry, pulse rate and blood pressure 4. Borkovec and Nau credibility rating - this will be used to assess the success of blinding Added as of 14/10/2008: All primary and secondary outcomes are measured at 1) baseline 2) pre-treatment (after a 4-week wait period to ensure participant's condition is stable) and 3) post-treatment on the 9th session. | — |
Countries
United Kingdom
Outcome results
None listed